This Website uses cookies which are essential for
providing our services and core website functionality. In
addition, if you click on "I AGREE", we will further use
analytical and advertising cookies to analyse your use of
our Website so that we can improve its functionality and
display content tailored according to your interests and
preferences, including on third party websites. We use
Google Analytics and its tracking and remarketing features
connected with Google Ads. This means that cookies on your
device will be placed and accessed by Google LLC in the USA
enabling us and third parties participating in the Google
advertising network to conduct conversion tracking and
remarketing activities across different websites and
devices. By accepting analytical and advertising cookies you
consent to the respective processing and sharing of your
personal data with Google LLC. You can withdraw your consent
and change your cookie preferences at any time by using our
Cookie preferences tool
. To refuse consent and continue without analytical and
advertising cookies, please click on "I DO NOT AGREE". For
more information see our
cookie policy
.
Lieber Besucher,
aus rechtlichen Gründen dürfen nur Angehörige
medizinischer Fachkreise Zugang zu Informationen über
verschreibungspflichtige Produkte erhalten. Teile dieser
Webseite stehen daher ausschließlich medizinischen
Fachkreisen zur Verfügung und sind mit einem Passwort
geschützt. Um Zugriff auf diese Informationen zu
erhalten, melden Sie sich bitte hier an.
Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo’s HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201)
Die Pressemeldungen in englischer Sprache finden Sie hier
Daiichi Sankyo
2020-12-18 11:38:50
Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi